You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 16, 2024

CLINICAL TRIALS PROFILE FOR TYVASO DPI


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for TYVASO DPI

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00147199 ↗ Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH) Completed United Therapeutics Phase 3 2005-06-01 This is a double-blind placebo-controlled clinical investigation into the efficacy and tolerability of inhaled treprostinil in patients with severe pulmonary arterial hypertension. The primary outcome is the change in 6-minute walk distance from baseline to week 12.
NCT00741819 ↗ Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects Completed United Therapeutics Phase 4 2008-09-01 This is a 24-month, multi-center, prospective, open-label, safety evaluation in PAH subjects following transition from a stable dose of inhaled iloprost (Ventavis). Subjects are to be evaluated for safety throughout the course of the study while secondary assessments will be conducted at Baseline, Week 6, Week 12, and Months 6, 12, 18 and 24 following initiation of treprostinil sodium.
NCT01266265 ↗ Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies Completed United Therapeutics 2010-12-01 A surveillance of respiratory tract related adverse events in patients treated with Tyvaso®(treprostinil) Inhalation Solution versus other FDA approved therapies
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for TYVASO DPI

Condition Name

Condition Name for TYVASO DPI
Intervention Trials
Pulmonary Arterial Hypertension 8
Interstitial Lung Disease 7
Pulmonary Hypertension 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for TYVASO DPI
Intervention Trials
Hypertension 14
Lung Diseases 9
Pulmonary Arterial Hypertension 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for TYVASO DPI

Trials by Country

Trials by Country for TYVASO DPI
Location Trials
United States 213
Austria 2
Israel 2
Canada 2
Puerto Rico 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for TYVASO DPI
Location Trials
North Carolina 12
California 12
Alabama 9
Texas 9
Pennsylvania 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for TYVASO DPI

Clinical Trial Phase

Clinical Trial Phase for TYVASO DPI
Clinical Trial Phase Trials
Phase 4 3
Phase 3 6
Phase 2/Phase 3 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for TYVASO DPI
Clinical Trial Phase Trials
Completed 12
Not yet recruiting 3
Recruiting 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for TYVASO DPI

Sponsor Name

Sponsor Name for TYVASO DPI
Sponsor Trials
United Therapeutics 15
Lung Biotechnology PBC 2
Bastiaan Driehuys 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for TYVASO DPI
Sponsor Trials
Industry 18
Other 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.